口腔癌发病过程中的阿迪波金及其作为一种新的治疗方法的潜力
Xue Wang1, Jiapeng Wang2, Xuemei Zhao1
1Department of Stomatology, Jilin Province FAW General Hospital, Jilin, 130000, China.
Naunyn-Schmiedeberg's archives of pharmacology
|March 8, 2025
概括
肥胖会通过脂肪细胞分泌的因素改变瘤微环境,从而影响口腔癌. 了解这些阿迪波基因为口腔癌治疗提供了潜在的新治疗点.
科学领域:
- 在瘤学瘤学.
- 代谢研究研究 代谢研究
- 免疫学 免疫学 免疫学
背景情况:
- 脂肪组织在癌症的发展中起着关键作用,特别是在脂质代谢和瘤生长方面.
- 肥胖显著影响瘤免疫微环境 (TME) 在口腔癌.
- 内脏白脂肪组织 (WAT) 包含脂肪细胞,免疫细胞和树皮成分,影响新陈代谢过程.
研究的目的:
- 审查脂肪细胞对口腔癌的影响.
- 详细介绍由脂肪细胞释放的介质,这些介质会影响口腔癌.
- 探索口癌进展中的阿迪波金作用背后的分子机制.
主要方法:
- 文献综述,重点关注脂肪组织,肥胖,脂肪蛋白和口腔癌.
- 在肥胖症中的脂肪组织内免疫细胞代谢的分析.
- 检查肥胖相关的口腔癌中的阿迪波金失调 (莱普丁和阿迪波内克丁).
主要成果:
- 肥胖脂肪组织中的免疫细胞依赖于氧化酸化,并显示M2巨细胞,Treg细胞,Th2细胞和eosinophils的增加.
- 脂肪细胞分泌的阿迪波金调节葡萄糖和脂质代谢,并与邻近的组织进行通信.
- 肥胖导致调节失调的脂肪基因形状,增加了勒素和减少了形素,促进了癌症的进展.
结论:
- 脂肪细胞通过分泌的中间体 (adipokines) 显著影响口腔癌的进展.
- 肥胖症中瘦素和皮内克丁的失调有助于形成一种支持瘤的环境.
- 了解阿迪波金在口腔癌中的作用的分子基础,为新的治疗策略提供了机会.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.6K
08:11Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics
Published on: March 26, 2018
7.6K
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
The Intrinsic Apoptotic Pathway
5.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.9K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
